ClinConnect ClinConnect Logo
Search / Trial NCT01526681

Registry of Avance® Nerve Graft's Utilization and Recovery Outcomes Post Peripheral Nerve Reconstruction

Launched by AXOGEN CORPORATION · Feb 2, 2012

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Sensory Nerve Mixed Nerve Motor Nerve Neurotization Nerve Injury Peripheral Nerve Injury

ClinConnect Summary

This clinical trial is studying the use of Avance® Nerve Graft for repairing nerve injuries and how patients recover after the surgery. The trial aims to gather real-life information on how well the graft works, its safety, and how it helps patients regain their nerve function. It is open to both men and women who have had nerve repair surgery using the Avance® Nerve Graft and have returned for at least one follow-up visit after their procedure.

To participate, individuals need to meet certain criteria, such as having a specific type of nerve injury and being able to attend follow-up appointments to check their progress. Participants can expect to undergo evaluations to assess their recovery, including sensory tests and questionnaires about their experience. This study will help improve our understanding of nerve repair techniques and may guide future treatments for nerve injuries. If you or a loved one are interested in joining, it's a good idea to discuss it with your healthcare provider to see if you meet the eligibility requirements.

Gender

ALL

Eligibility criteria

  • Primary Study Criteria (RANGER Avance):
  • Inclusion Criteria:
  • Males and Females who have undergone nerve repair using the Avance® Nerve Graft for the repair of a nerve injury
  • Returned for at least one post-operative follow-up visit
  • Exclusion Criteria:
  • • Subject who in the opinion of the investigator, have not or likely will not complete at least some portion of the investigator's recommended follow-up.
  • Addendum 1 (MATCH) Criteria:
  • Inclusion Criteria:
  • Have nerve transection injuries to the upper extremity;
  • Have undergone tension free end to end nerve coaptation on both the proximal and distal portion of the nerve gap with nerve autograft or nerve entubulation with nerve tube conduit at a participating ANG-CP-005 registry site after 2004 and;
  • Have completed sufficient follow-up assessments at a regeneration rate of 2mm/day to determine the outcomes of the repair or is willing to comply with site specific post-operative care procedures and assessments to determine the outcome of the repair.
  • Exclusion Criteria:
  • Direct nerve repairs;
  • Nerve gaps greater than 70mm;
  • Subjects who, in the opinion of the investigator, were non-compliant to the investigator's post-operative treatment or rehabilitation instructions;
  • Any subject who at the discretion of the Investigator is not suitable for inclusion in the study.
  • Addendum 2 (Sensation-NOW) Criteria:
  • Inclusion Criteria:
  • Female ≥ 18 years old
  • Undergo post mastectomy autologous breast reconstruction with one type of autologous flap (no stacked reconstructions or use of implant with autologous flap)
  • Neurotization must be completed using a donor nerve from the flap and a recipient nerve from the chest
  • * Complete Sensory Assessment Testing with Semmes Weinstein Monofilaments (SWMF) and the following Breast-Q Questionnaires 60 - 120 days post-reconstruction:
  • Breast-Q Physical Well Being of the Chest
  • Breast-Q Satisfaction with Breast
  • Breast-Q Physical Well Being of the Abdomen
  • Breast-Q Abnormal Breast Sensations
  • Breast-Q Impact of Breast Sensation on Quality of Life
  • Breast-Q Return of Breast Sensation
  • Able to provide informed consent and are willing to comply with post-operative care procedures and assessments
  • Exclusion Criteria:
  • Surgical history of secondary revision surgery for partial or total flap loss
  • Bilateral reconstruction with non-uniform treatment (i.e. 1 reconstructed breast is non-neurotized, 1 reconstructed breast is neurotized)
  • Currently prescribed medication known to impact nerve regeneration or to cause peripheral neuropathy
  • Currently undergoing IV chemotherapy or radiation
  • Any subject who at the discretion of the Investigator is not suitable for inclusion in the study or is unlikely to comply with follow-up schedule
  • Additional Eligibility criteria to Modules
  • Module 1: Native Skin Reconstructions with and without neurotization.
  • Buried flap reconstructions from nipple sparing mastectomy or skin sparing mastectomy OR a breast reconstruction from a skin sparing mastectomy with exposed flap skin in the peri-areolar region.
  • Sensory assessments must be completed on ≥ 8 Zones of Native Skin.
  • Center zone measurement may be on either Native Skin or Flap Skin.
  • All Inner and Outer zone measurements must be on Native Skin.
  • De-identified photo of the breast reconstruction with 9 zones identified.

About Axogen Corporation

Axogen Corporation is a leading medical technology company specializing in the development and commercialization of innovative regenerative medicine solutions for peripheral nerve repair. With a focus on advancing surgical techniques and improving patient outcomes, Axogen offers a comprehensive portfolio of products designed to facilitate nerve regeneration and restore function after injury. The company is committed to clinical research and evidence-based practices, collaborating with healthcare professionals to enhance the understanding and treatment of peripheral nerve injuries. Through its dedication to innovation and patient care, Axogen aims to transform the landscape of nerve repair and improve the quality of life for patients worldwide.

Locations

Phoenix, Arizona, United States

Phoenix, Arizona, United States

Orange, California, United States

San Francisco, California, United States

Stanford, California, United States

Aurora, Colorado, United States

Miami, Florida, United States

Tampa, Florida, United States

Atlanta, Georgia, United States

Kansas City, Kansas, United States

Kansas City, Kansas, United States

Lexington, Kentucky, United States

Metairie, Louisiana, United States

Baltimore, Maryland, United States

Baltimore, Maryland, United States

Bethesda, Maryland, United States

Minneapolis, Minnesota, United States

Columbia, Missouri, United States

Omaha, Nebraska, United States

Rutherford, New Jersey, United States

Charlotte, North Carolina, United States

Durham, North Carolina, United States

Cincinnati, Ohio, United States

Cincinnati, Ohio, United States

Cleveland, Ohio, United States

Columbus, Ohio, United States

Columbus, Ohio, United States

Philadelphia, Pennsylvania, United States

Mount Pleasant, South Carolina, United States

Germantown, Tennessee, United States

Nashville, Tennessee, United States

Nashville, Tennessee, United States

Dallas, Texas, United States

Fort Worth, Texas, United States

Fort Worth, Texas, United States

Houston, Texas, United States

Houston, Texas, United States

Lubbock, Texas, United States

Richardson, Texas, United States

San Antonio, Texas, United States

San Antonio, Texas, United States

Seattle, Washington, United States

Vienna, , Austria

Toronto, Ontario, Canada

Edgbaston, Birmingham, United Kingdom

Miami, Florida, United States

Durham, North Carolina, United States

Houston, Texas, United States

Lubbock, Texas, United States

Richmond, Virginia, United States

Washington, District Of Columbia, United States

Las Vegas, Nevada, United States

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials